מקדם חוב לטווח ארוך להון Biote Corporation (BTMD)

biote Corp. (BTMD) leads the personalized hormone correction segment, leveraging a proprietary subcutaneous implant method and a medical professional training system. Market capitalization is based on the sale of bioidentical pellets for individuals experiencing age-related changes. Meanwhile, R&D development is focused on applied software and the refinement of protocols, as confirmed by this price chart. The current metric stands at 0.00.

This metric measures the ratio of liabilities with a maturity exceeding one year to total equity, determining the issuer's degree of financial autonomy. The current long-term credit leverage at 0.00 reflects biote Corp. (BTMD) dependence on borrowed funds to scale its hormone therapy network and expand its nutraceutical product line to diversify revenue.